White Papers

11.11.24

Prenatal Vaccines in Medicaid and CHIP: Current Reimbursement and Policies to Increase Access

Below is an edited excerpt from a recent Manatt Health paper. Click here to read the full text. Despite the demonstrated effectiveness of prenatal vaccines, uptake remains low. This puts mothers i and babies at risk. Vaccines administered prenatally (i.e., during a pregnancy) ...


06.26.24

Patient Impact of the Inflation Reduction Act

As part of IRA implementation and in advance of calendar year 2025, which is when the implementation of Part D redesign changes accelerate, CMS could take steps to protect beneficiaries by preserving access and increasing transparency.


06.20.24

State Medicaid Coverage and Reimbursement of Adult Vaccines Administered by Physicians and Pharmacis

Effective October 2023, federal law requires Medicaid programs to cover all recommended adult vaccines administered by physicians with no cost sharing for all eligibility groups.


02.25.24

Future of Health: The Emerging Landscape of Augmented Intelligence in Health Care

In this comprehensive report, the AMA and Manatt Health explore the transformational potential of augmented intelligence (AI) in the practice of medicine and outline practical considerations for physicians who are using or considering using AI-based tools for clinical or administrative purposes.


02.06.24

Future of Health: Imperatives for Advancing Data Sharing to Support Digitally Enabled Care

Traditional brick-and-mortar health care organizations and digital health companies are actively partnering to provide novel, digitally enabled care models to patients. Despite the potential of these new care models, it is critical that they do not inadvertently increase fragmentation of health ...




09.25.23

Anti-Obesity Medications as Medicare Part D Drugs: Legal and Health Policy Rationales

Obesity is a complex, multifactorial disease that has serious health consequences, affects millions of Americans and drives hundreds of billions of dollars in annual health care spending.




09.07.23

Achieving Diversity in Clinical Trials: Expanding Hospital Capacity to Offer Clinical Trials in the

The inclusion of racial and ethnic groups in clinical trials has been a national priority for decades, but progress toward that end has been limited.




12.05.22

340B Anti-Discrimination Provisions: A Review of Proposed and Enacted Legislation by State

The 340B Drug Pricing Program, which was enacted in 1992 by Section 340B of the federal Public Health Services Act, requires pharmaceutical manufacturers that participate in the Medicaid program to provide covered outpatient drugs at significantly reduced prices to certain health care providers ...